[Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
Ikeda
Kazuto
K
Department of Internal Medicine, Kobe Japan Post Hospital.
Fukagawa
Masafumi
M
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption; D002117:Calcitriol / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage; D015195:Drug Design; D004359:Drug Therapy, Combination; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000008:administration & dosage* / Q000494:pharmacology / Q000502:physiology; D044168:Receptor, Parathyroid Hormone, Type 1 / Q000502:physiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone; D044168:Receptor, Parathyroid Hormone, Type 1; D002117:Calcitriol